Yang Dajun Amends Initial Ownership Statement for Ascentage Pharma
| Field | Detail |
|---|---|
| Company | Yang Dajun |
| Form Type | 3/A |
| Filed Date | Mar 23, 2026 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: insider-ownership, amendment, form-3, compliance
TL;DR
**Insider Yang Dajun just amended their ownership filing for Ascentage Pharma.**
AI Summary
This 3/A filing is an amendment to an initial statement of beneficial ownership for Yang Dajun, a reporting person, related to ASCENTAGE PHARMA GROUP INTERNATIONAL (CIK: 0002023311). Filed on March 23, 2026, this amendment updates the original Form 3, indicating a change or correction in Dajun's ownership details. For investors, this matters because changes in insider ownership, even minor amendments, can signal shifts in confidence or compliance, which could influence stock perception.
Why It Matters
This amendment clarifies or corrects an insider's reported stake, providing a more accurate picture of their ownership in Ascentage Pharma Group International.
Risk Assessment
Risk Level: low — This filing is an amendment to an initial ownership statement, typically correcting minor details rather than indicating a major new transaction.
Analyst Insight
Investors should note the amendment but await further details on what specific information was changed. Unless the amendment reveals a significant change in ownership or a material correction, its immediate impact is likely minimal.
Key Players & Entities
- Yang Dajun (person) — Reporting Person
- ASCENTAGE PHARMA GROUP INTERNATIONAL (company) — Issuer
- 0002059751 (person) — Yang Dajun's CIK
- 0002023311 (company) — ASCENTAGE PHARMA GROUP INTERNATIONAL's CIK
FAQ
What is the purpose of a 3/A filing?
A 3/A filing is an amendment to a Form 3, which is an initial statement of beneficial ownership of securities. It is used to correct or update information previously reported in the original Form 3, as indicated by the 'Amend' description in the filing.
Who is the reporting person in this filing and what company are they associated with?
The reporting person is Yang Dajun (CIK: 0002059751), and they are associated with ASCENTAGE PHARMA GROUP INTERNATIONAL (CIK: 0002023311), which is the issuer.
When was this 3/A filing accepted by the SEC?
This 3/A filing was accepted by the SEC on March 23, 2026, at 19:05:24.
Filing Stats: 829 words · 3 min read · ~3 pages · Grade level 9.5 · Accepted 2026-03-23 19:05:24
Filing Documents
- marketforms-72728.html (3/A)
- marketforms-72728.xml (3/A) — 11KB
- poa.htm (EX-24) — 6KB
- 0001213900-26-033123.txt ( ) — 19KB
From the Filing
SEC FORM 3/A SEC Form 3 FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response: 0.5 1. Name and Address of Reporting Person * Yang Dajun (Last) (First) (Middle) 700 KING FARM BLVD STE 510 (Street) ROCKVILLE MARYLAND 20850 (City) (State) (Zip) UNITED STATES (Country) 2. Date of Event Requiring Statement (Month/Day/Year) 03/18/2026 3. Issuer Name and Ticker or Trading Symbol ASCENTAGE PHARMA GROUP INTERNATIONAL [ AAPG ] 3a. Foreign Trading Symbol 5. If Amendment, Date of Original Filed (Month/Day/Year) 03/19/2026 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner X Officer (give title below) Other (specify below) Chairman and CEO 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person Table I - Non-Derivative Securities Beneficially Owned 1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5) Ordinary Shares 1,097,994 D Ordinary Shares 22,054,131 I See Footnote (1) (1) Ordinary Shares 312,534 I See Footnote (2) (2) Ordinary Shares 14,089,111 I See Footnote (3) (3) Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5) Date Exercisable Expiration Date Title Amount or Number of Shares Options (4) 11/26/2035 Ordinary Shares 143,463 $ 8.14 (5) D Options (4) 11/26/2035 Ordinary Shares 103,364 $ 8.14 I See Footnote (6) (6) Restricted stock units (7) (7) Ordinary Shares 143,463 $ 0 D Restricted stock units (7) (7) Ordinary Shares 103,364 $ 0 I See footnote (6) (6) Explanation of Responses: 1. Shares held by Dajun Yang Dynasty Trust, of which the Reporting Person is the investment advisor. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. 2. Shares held by Reporting Person's spouse. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. 3. Shares held by HealthQuest Pharma Limited, an entity controlled by the Reporting Person's spouse. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. 4. The stock options vest in four equal increments on each of 11/26/2026, 2027, 2028 and 2029. 5. The exercise price for the stock options is in HKD, and the exercise price included in the table represents conversion to USD based on the exchange rate on the date of grant. 6. Securities held by the Reporting Person's spouse. The Reporting Person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. 7. Each restricted stock unit (RSUs) represents a contingent right to receive one Ordinary Share of the Issuer upon vesting. The RSUs vest in four equal increments on each of 11/26/2026, 2027, 2028 and 2029 and have no expiration date. Remarks: This form is filed using a special power of attorney. Thomas J. Knapp 03/18/2026 ** Signature of Reporting Person Date Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note